MediWound Ltd.
MediWound develops bio-therapeutic solutions for tissue repair and regeneration. They market NexoBrid for removing dead tissue from burn victims. EscharEx has completed Phase II trials for chronic wound debridement. MW005 is in Phase I/II for treating low-risk basal cell carcinoma. The company was incorporated in 2000 and is headquartered in Israel.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 4.4% in each of the last 5 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 21.0% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
Key Financial Data